bluebird bio Announces September Investor Events
August 29 2022 - 8:00AM
Business Wire
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members
of the management team will participate in the following upcoming
investor conferences:
- 2022 Wells Fargo Healthcare Conference, Thursday, September 8,
at 9:10 a.m. ET at the Encore Boston Harbor, Everett, MA
- Morgan Stanley 20th Annual Global Healthcare Conference,
Tuesday, September 13, at 8:35 a.m. ET at the Sheraton New York,
New York, NY
To access the live webcast of bluebird bio’s presentations,
please visit the “Events & Presentations” page within the
Investors & Media section of the bluebird bio website at
http://investor.bluebirdbio.com. A replay of the webcasts will be
available on the bluebird bio website for 90 days following the
event.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days. With a dedicated
focus on severe genetic diseases, bluebird has industry-leading
clinical and research programs for sickle cell disease,
beta-thalassemia and cerebral adrenoleukodystrophy and is advancing
research to apply new technologies to these and other diseases. We
custom design each of our therapies to address the underlying cause
of disease and have developed in-depth and effective analytical
methods to understand the safety of our lentiviral vector
technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo
gene therapy data set in the world—setting the standard for
industry. Today, bluebird continues to forge new paths, combining
our real-world experience with a deep commitment to patient
communities and a people-centric culture that attracts and grows a
diverse flock of dedicated birds.
For more information, visit bluebirdbio.com or follow us on
social media at @bluebirdbio, LinkedIn, Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220829005358/en/
Investors & Media Investors: Courtney O’Leary,
978-621-7347 coleary@bluebirdbio.com
Media: Sarah Alspach, 857-299-6198
sarah.alspach@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024